SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit's post-earnings plunge dominates trader chatter after the company beat Q4 but issued weak FY2027 guidance, admitting pricing drove TurboTax customers away and unveiling low-cost fixes. Retail sentiment is extremely bullish despite the selloff, with bulls citing valuation and repositioning while bears point to AI disruption and structural growth slowdown.

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is trending as its post-earnings crash becomes the market's focal point, with the stock on pace for its worst month in six years after Q2 results and guidance cuts intensified worries about weak athletic footwear demand and the Foot Locker acquisition.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending as investors focus on its planned NBCUniversal spin-off to unlock value, alongside a proposed Sky-ITV deal and box-office strength from 'The Odyssey' and Minions. Community sentiment is split, with bulls touting a low valuation and high dividend yield, while bears cite persistent price declines and broadband subscriber losses.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Sentiment is split as bullish traders highlight OpenAI-driven lab automation cost cuts and DARPA ICE Phase III progress, while skeptics point to ongoing cash burn and dilution risks.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

NCLH traders are frustrated that the stock keeps fading despite falling oil prices and easing Iran tensionsfactors that should lift cruise names. The community sees a disconnect between bullish macro tailwinds and the stock's persistent weakness, with many blaming heavy shorting and manipulation while awaiting a breakout back toward the $18$20 range.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strive is surging on its aggressive Bitcoin accumulation and an analyst endorsement as a top crypto pick, while extreme short interest fuels strong conviction that a squeeze is imminent as BTC breaks higher and the stock outperforms peers like MSTR.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

KURA is surging on CEO Troy Wilson's second significant open-market share purchase, which the community reads as a strong confidence signal amid ongoing KOMZIFTI launch momentum and persistent short interest. Traders are also speculating about a potential Kyowa Kirin acquisition.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

The stock is rallying hard as the sector gets a boost from Modernas cancer vaccine trial success, but unlike peers that pulled back, ARCT is holding its gains. Retail traders are calling it undervalued versus larger mRNA players, with chatter focusing on the companys buyout potential and its robust cash runway.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as bulls and bears clash over a sharp selloff to 52-week lows, with bulls highlighting 53% revenue growth and strong margins while bears cite slowing growth and a wave of analyst price-target cuts. Heavy options chatter and concerns over the company's buyback plan are fueling the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras (CBRS) is at the center of intense debate as traders weigh its massive AI growth potential against heavy bearish pressure from insider selling, staggered lockup expirations, and persistent valuation concerns. Bulls point to the company's OpenAI collaboration and $20B+ backlog, while bears argue the upcoming Nvidia earnings and chip competition could crush the stock further.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immunic advances MS drug toward key Phase 3 data, expects results by year-end

Immunic advances MS drug toward key Phase 3 data, expects results by year-end...

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire NEW YORK, Aug. 11, 2026 Leadership Team Expanded with Key Executive Appointments, Including Chief Executive...

Immunic Appoints Elena Ridloff to Board of Directors

Immunic Appoints Elena Ridloff to Board of Directors Immunic Appoints Elena Ridloff to Board of Directors PR Newswire NEW YORK, Aug. 10, 2026 Appointment Strengthens Board with Financial, Capital Markets and Commercial Leadership Expertise as the Company Approaches Pivotal Phase 3 ENSURE Readout in...

Immunic to Participate in Investor Conferences in July

Immunic to Participate in Investor Conferences in July Immunic to Participate in Investor Conferences in July PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral therapies...

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic to Participate in Investor, Industry and Scientific Conferences in June Immunic to Participate in Investor, Industry and Scientific Conferences in June PR Newswire NEW YORK, June 10, 2026 NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company...

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026...

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials...

Immunic Names Erik Lundgren Chief Executive Officer

(RTTNews) - Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1...

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer PR Newswire NEW YORK, May 27, 2026 Proven Leader with Deep Multiple Sclerosis Expertise; Played Key...

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.

Immunic Inc

IMUX Stock Jumps 6% Pre-Market Today – Here’s The Latest Update On Its Compliance With Nasdaq Listing Rules 

Equity

Bearish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMUX Immunic Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest IMUX News